Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report
- PMID: 20052713
- PMCID: PMC4113953
- DOI: 10.1002/cncr.24834
Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report
Abstract
Background: Primary central nervous system (CNS) post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare complication of solid organ transplantation. The objectives of this study were to define the clinical, radiologic, and pathologic features of this disease and to explore the impact of treatment on patient outcomes.
Methods: The authors reviewed the databases of participating institutions of the International Primary CNS Lymphoma Collaborative Group for cases of PCNS-PTLD. Thirty-four patients who had pathologically confirmed PCNS-PTLD without evidence of systemic PTLD were investigated retrospectively.
Results: The median time from transplantation to diagnosis of PCNS-PTLD was 4.4 years. Disease usually was multifocal and involved any location of the brain but was most common in the cerebral hemispheres, usually in the subcortical white matter or basal ganglia. Radiographically, all lesions enhanced either homogenously or in a ring-enhancing pattern. Cerebral biopsy was required to establish diagnosis in most patients. Most patients had monomorphic, Epstein-Barr virus (EBV)-positive disease of B-cell origin. Response rates were high regardless of treatment type, and the median survival was 47 months. Age was the only factor predictive of survival.
Conclusions: The current study demonstrated that PCNS-PTLD is typically an EBV-induced B-cell lymphoma that is responsive to treatment with favorable survival in many patients. An aggressive approach to tissue confirmation of diagnosis and treatment with chemotherapy or radiotherapy should be strongly considered.
Conflict of interest statement
CONFLICT OF INTEREST DISCLOSURES
The authors made no disclosures.
Figures
Comment in
-
Primary central nervous system post-transplantation lymphoproliferative disorder.Cancer. 2010 Jul 15;116(14):3521; author reply 3521-2. doi: 10.1002/cncr.25340. Cancer. 2010. PMID: 20564159 No abstract available.
Similar articles
-
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.Ann Hematol. 2021 Aug;100(8):2043-2050. doi: 10.1007/s00277-021-04548-2. Epub 2021 May 11. Ann Hematol. 2021. PMID: 33973053
-
Post-transplantation lymphoproliferative disorders (PTLD) localized in the central nervous system: report from an international survey on PTLD.Saudi J Kidney Dis Transpl. 2013 Mar;24(2):235-42. doi: 10.4103/1319-2442.109563. Saudi J Kidney Dis Transpl. 2013. PMID: 23538344 Review.
-
Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma.J Neurooncol. 2015 Nov;125(2):297-305. doi: 10.1007/s11060-015-1903-1. Epub 2015 Sep 4. J Neurooncol. 2015. PMID: 26341369
-
A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.Neurosurgery. 2013 Jun;72(6):960-70; discussion 970. doi: 10.1227/NEU.0b013e31828cf619. Neurosurgery. 2013. PMID: 23685504 Free PMC article.
-
[Primary central nervous system post-transplant lymphoproliferative disorders].Brain Nerve. 2014 Aug;66(8):947-54. Brain Nerve. 2014. PMID: 25082316 Review. Japanese.
Cited by
-
Neurological symptoms in a post-transplant patient: a cautionary tale.J Neurol. 2013 Jan;260(1):309-11. doi: 10.1007/s00415-012-6719-8. Epub 2012 Oct 27. J Neurol. 2013. PMID: 23104125 No abstract available.
-
Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.Neurology. 2013 Jul 16;81(3):256-63. doi: 10.1212/WNL.0b013e31829bfd8f. Epub 2013 Jun 14. Neurology. 2013. PMID: 23771486 Free PMC article.
-
Successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation - a case study.Cent Eur J Immunol. 2015;40(1):122-5. doi: 10.5114/ceji.2015.50845. Epub 2015 Apr 22. Cent Eur J Immunol. 2015. PMID: 26155195 Free PMC article.
-
An Approach to Neurological Disorders in a Kidney Transplant Recipient.Kidney360. 2020 Jun 16;1(8):837-844. doi: 10.34067/KID.0002052020. eCollection 2020 Aug 27. Kidney360. 2020. PMID: 35372958 Free PMC article. Review.
-
Neurological complications of solid organ transplantation.Neurohospitalist. 2013 Jul;3(3):152-66. doi: 10.1177/1941874412466090. Neurohospitalist. 2013. PMID: 24167649 Free PMC article.
References
-
- Taylor AL, Marcus R, Bradley JA. Post-transplant lympho-proliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56:155–167. - PubMed
-
- Harris NL, Swerdlow SH, Frizzera G, Knowles GM. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. pp. 264–269.
-
- Schneck SA, Penn I. Cerebral neoplasms associated with renal transplantation. Arch Neurol. 1970;22:226–233. - PubMed
-
- Snanoudj R, Durrbach A, Leblond V, et al. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation. 2003;76:930–937. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical